Lowest Price Guaranteed From USD 4,799
Published
January 2023
Pages
565
View Count
51924
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
The current opportunity for curative digital solutions is prominent, representing nearly 70%-80% of the total market share of the digital therapeutics
-- Founder and CEO, a UK based small-sized company
The global digital therapeutics market is anticipated to grow at a compound annual growth rate (CAGR) of 20% during the period 2022 – 2035 and is expected to be worth around USD 20 billion by 2035. Digital Therapeutics, popularly known as DTx, represent a digital health solution which delivers medical interventions directly to the patients in order to treat, manage and prevent a disease. Such solutions usually employ evidence based and clinically validated software or technologies, in order to capture real-time / real world patient data and provide improved curative response. Considering the ongoing digitization efforts and transformation of the healthcare sector, digital therapeutics have garnered significant attention from industry stakeholders and investors alike. Further, government organizations have actively undertaken initiatives, such as enactment of legislation, publishing laws and establishment of regulations, in the digital therapeutics industry. For instance, the USFDA sanctioned the Breakthrough Device Designation Program for granting approvals to digital therapeutics. It is worth mentioning that, till September 2022, around 730 digital health products (including digital therapeutics, wellness apps and digital biomarkers) had been approved by the USFDA. A similar trend was observed in other countries, such as the UK, Germany, Denmark and South Korea, where regulatory authorities have published regulations pertaining to digital therapeutics and digital health solutions. The current activity in this market and the growing demand for such solutions will drive the market growth during the forecast period.
The Digital Health Market: Focus on Digital Therapeutics (3rd Edition), 2023-2035: Distribution by Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), Purpose of Solution (Medication Replacement and Medication Augmentation), Type of Business Model (B2B and B2C), Target Therapeutic Area (Cardiovascular Disorders, Chronic Pain, Mental Health Problems, Metabolic Disorders, Neurological Disorders Respiratory Disorders, Sleep Disorders, Substance use Disorders and Other Disorder) and Key Geographical Regions (North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current landscape, market size and future opportunity, offering an informed opinion on the likely adoption of digital therapeutic solutions in the healthcare industry, over forecast period. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. The report answers following key questions related to this domain.
Owing to their multiple benefits, including ease of access, shorter development timelines, versatile delivery platforms, decreased cost of treatment, personalized treatment options, enhanced medication adherence, promotion of healthy lifestyle and remote access to healthcare providers for patients and vice versa, digital therapeutics have emerged as a promising alternative to conventional medication. The benefits offered by these solutions and the growing demand for remote and digital solutions across the world, post the pandemic, will drive market growth in the long term.
The digital therapeutics market landscape features an extensive list of more than 150 large, mid-sized, small and very small players. It is worth highlighting that over 400 digital therapeutic solutions are presently available in the market / being developed by several industry stakeholders for various target indications. It is also worth noting that majority (more than 100) of the approved / under development digital therapeutic solutions target mental health problems. Within the mental health area, indications like stress, anxiety and depression are mainly targeted by the companies. This is followed by solutions targeting neurological and metabolic disorders.
The COVID-19 pandemic, coupled to the subsequent enforcement of mandatory social distancing measures, has created an enormous demand for remote patient engagement. Further, the evolving regulatory and clinical settings around the world have created an ample opportunity for industry stakeholders. In addition, regulatory authorities and government bodies have provided considerable support for digital therapeutics over the past few years. Moreover, the growing interest of investors in this market can be validated by the significant rise in funding activity in the recent past. Additionally, various big pharma players have undertaken several key initiatives, including strengthening their product portfolio, entering into strategic deals and making significant financial investments. Considering the active involvement of well-established industry players, the new entrants, as well as big pharma players and government organizations, the development pipeline of digital therapeutics is likely to grow further, over the forecast period. Furthermore, rising incidence of chronic diseases and associated healthcare costs will drive the adoption of digital disease management as more data pours in proving the efficacy of such devices. As per the National Center for Chronic Disease Prevention and Health Promotion, chronic diseases like diabetes, cardiovascular disease and stroke, Alzheimer’s, cancer, obesity and arthritis are some of the leading indications that account for a huge proportion of healthcare expenditure in the US.
Driven by the rising interest in digital and remote health solutions, the future opportunities and growth associated with the digital therapeutics, the global market is anticipated to grow at compound annual growth rate (CAGR) of 20% during the period 2022 – 2035 and is expected to be worth around USD 20 billion by 2035. Specifically, in terms of type of product, this global market is anticipated to be driven by standalone software applications based digital therapeutics, which target metabolic disorders. Diabetes management through digital therapeutics has garnered a lot of attention, with at least six prescription digital therapeutics approved in the US. All these six products received 510(k) clearance and require a prescription from a clinician.
In addition to this, presently, close to 90% of the market is captured by players based in North America and Europe. A bill, Access to Prescription Digital Therapeutics Act of 2023, was introduced in the Senate in March 2023; when passed, it will expand the coverage of prescription digital therapeutics and, hence, their adoption in the US. However, in the long term, the digital therapeutics market in Asia is anticipated to grow at a relatively faster pace during the forecast period. Rising incidence of chronic diseases like diabetes, increasing use of smartphones and access to improved internet services will be the key market drivers.
Examples of key players engaged in digital therapeutics market (which have also been profiled in this report) include (in alphabetical order) Ampersand Health, Akili Interactives, Better Therapeutics, Brain+, Click Therapeutics, CogniFit, GAIA, Healios, JOGO Health, Jolly Good, KORE Digital Health Therapeutics, Livongo Health, Lucid, MedRhythms, Pear Therapeutics, Redicare Control, Susmed, The Learning Corp, Voluntis and WellDoc.
Several recent developments have taken place in the field of digital therapeutics. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
Global Digital Therapeutics Market: Market Segmentations.
| Key Report Attributes | Details | |
|
Forecast Period |
2023 – 2035 |
|
|
Type of Solution |
Standalone Software Application, Software Application + Device, Software Application + AI Support, Software Application + Personal Coach, Software Application + Device + AI Support, Software Application + Device + Personal Coach and Others | |
|
Type of Therapy |
Curative Solutions, and Preventive Solutions | |
|
Purpose of Solution |
Medication Replacement and Medication Augmentation | |
|
Type of Business Model |
B2B and B2C | |
|
Therapeutic Area |
Cardiovascular disorders, Chronic Pain, Mental Health Problems, Metabolic disorders, Neurological disorders, Respiratory disorders, Sleep disorders, Substance use disorders and Other disorders | |
|
Key Geographical Area |
North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World | |
The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in digital therapeutics industry. Amongst other elements, the report includes:
The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders (in alphabetical order of company name):
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Answer: Digital therapeutics, also known as DTx, represent a type of digital health solution which delivers medical interventions directly to the patients, using an evidence based, clinically validated software or a combination of software, in order to treat, manage and prevent a disease or disorder
Answer: Majority (close to 30%) of the marketed / under development digital therapeutic solutions target mental health disorders. This can be attributed to the steep rise observed in THE incident of mental health disorders, such as anxiety, depression and stress, during and post the pandemic, across the globe. It is also worth highlighting that neurological and metabolic disorders are other popular therapeutic areas targeted by the digital therapeutic solutions.
Answer: The global digital therapeutics market is anticipated to grow at a compound annual growth rate of 20% over the next 13 years and is expected to be worth around USD 20 billion by 2035.
Answer: Currently, North America and Europe collectively hold 80% of the market share. In the long run, the digital therapeutics market in Asia is likely to grow at a relatively faster pace.
Answer: Digital therapeutic solutions are priced based on factors, such as complexity, target patient population, cost of development and delivery, competition, perceived value and regulatory settings. Complex solutions utilizing technologies, such as artificial intelligence or machine learning, may be more expensive.
Answer: Owing to the lucrative market opportunity associated with digital therapeutics, several investors have collectively invested over USD 20 billion.
Answer: Commercialization agreements, pilot product offerings and product / technology integration agreements are the most common type of partnership models adopted by stakeholders engaged in the digital therapeutics’ domain.
Answer: Most of the players involved in the digital therapeutics’ domain have adopted the in-bound marketing strategies in order to enhance their company and product visibility. It is worth highlighting that majority of the players have used Facebook, You-Tube and LinkedIn as the most preferred social media platforms for in-bound marketing.
Contents
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Digitization in the Healthcare Sector
3.3. Next-Generation Healthcare Solutions
3.4. Key Concepts Associated with Digital Health Solutions
3.4.1. Cognitive Behavioral Therapy (CBT)
3.4.2. Internet of Things (IoT)
3.4.3. Big Data
3.4.4. Artificial Intelligence (AI)
3.4.5. Gamification
3.5. Overview of Digital Therapeutics
3.5.1. Key Strategic Initiatives
3.5.1.1. Digital Therapeutics Alliance (DTA)
3.5.1.2. Personal Connected Health (PCH) Alliance
3.5.1.3. Programs Initiated by The Centers for Disease Control and Prevention (CDC)
3.5.1.4. Health Insurance Portability and Accountability Act (HIPAA)
3.5.1.5. National Health Service (NHS) Guidelines
3.5.1.6. United States Food and Drug Administration (USFDA) Regulations for Digital Therapeutics
3.5.2. Typical Development and Commercialization Path for Digital Therapeutics
3.5.2.1. Discovery and Preclinical Phase
3.5.2.2. Clinical Trials and Validation
3.5.2.3. Negotiation Involving Insurance Providers / Payers
3.5.2.4. Distribution and Marketing
3.6 Concluding Remarks
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Digital Therapeutics: Overall Market Landscape
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Type of Solution
4.2.3. Analysis by Type of Therapy
4.2.4. Analysis by Purpose of Solution
4.2.5. Analysis by Target Indication
4.2.6. Analysis by Therapeutic Area
4.2.7. Analysis by Target Population
4.3. Digital Therapeutics: Additional Information
4.3.1. Analysis by Requirement of Prescription
4.3.2. Analysis by Duration of Course
4.3.3. Analysis by Cost of Solution
4.4. Digital Therapeutics: List of Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Type of Business Model
4.4.4. Analysis by Location of Headquarters
4.5. Leading Developers: Analysis by Number of Digital Therapeutic Solutions
4.6. Leading Developers: Analysis by Portfolio Strength, Target Indication, and Company Size (4D Bubble Representation)
4.7. Analysis by Therapeutic Area and Company Size (Tree Map Representation)
4.8. Analysis of Regional Activity (World Map Representation)
5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions / Key Parameter
5.3. Methodology
5.4. Key Therapeutic Areas
5.4.1. Product Competitive Analysis: Digital Therapeutics Targeting Cardiovascular Disorders
5.4.2. Product Competitive Analysis: Digital Therapeutics Targeting Mental Health Problems
5.4.3. Product Competitive Analysis: Digital Therapeutics Targeting Metabolic Disorders
5.4.4. Product Competitive Analysis: Digital Therapeutics Targeting Neurological Disorders
5.4.5. Product Competitive Analysis: Digital Therapeutics Targeting Substance Use Disorders
5.4.6. Product Competitive Analysis: Digital Therapeutics Targeting Other Therapeutic Areas
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Akili Interactive
6.2.1. Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Big Health
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. dreem
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. Kaia Health
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. MindMaze
6.6.1. Company Overview
6.6.2. Product Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Omada Health
6.7.1. Company Overview
6.7.2. Product Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Pear Therapeutics
6.8.1. Company Overview
6.8.2. Product Portfolio
6.8.3. Recent Developments and Future Outlook
6.9. Vida Health
6.9.1. Company Overview
6.9.2. Product Portfolio
6.9.3. Recent Developments and Future Outlook
6.10. Voluntis
6.10.1. Company Overview
6.10.2. Product Portfolio
6.10.3. Recent Developments and Future Outlook
6.11. WellDoc
6.11.1. Company Overview
6.11.2. Product Portfolio
6.11.3. Recent Developments and Future Outlook
6.12. Wellthy Therapeutics
6.12.1. Company Overview
6.12.2. Product Portfolio
6.12.3. Recent Developments and Future Outlook
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Digital Therapeutics: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Status
7.3.3. Analysis by Trial Registration Year and Trial Status
7.3.4. Analysis by Trial Phase
7.3.5. Analysis by Type of Study
7.3.6. Analysis by Study Design
7.3.7. Analysis by Study Age
7.3.8. Analysis by Gender of Patients
7.3.9. Analysis of Patients Enrolled by Trial Registration Year
7.3.10. Analysis by Type of Sponsor
7.3.11. Analysis by Focus Area
7.3.12. Analysis by Geography
7.3.13. Analysis by Trial Registration Year, Recruitment Status and Geography
7.3.14. Analysis of Patients Enrolled by Geography
7.4. Clinical End-Points Analysis
8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Type of Funding Models
8.3. Digital therapeutics: List of Funding and Investments
8.3.1. Analysis of Number of Funding Instances by Year of Establishment and Type of Funding
8.3.2. Analysis of Funding Instances by Year
8.3.3. Analysis of Amount Invested by Year
8.3.4. Analysis by Type of Funding
8.3.5. Analysis of Instances and Amount Invested by Type of Therapy
8.3.6. Analysis by Therapeutic Area
8.3.7. Analysis by Geography
8.3.8. Most Active Players: Analysis by Number of Instances
8.3.9. Most Active Players: Analysis by Amount Raised
8.3.10. Most Active Investors: Analysis by Number of Instances
8.4. Concluding Remarks
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Digital Therapeutics: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.2.1. Analysis by Year of Partnership and Type of Partnership
9.3.2.2. Analysis by Type of Partnership and Company Size
9.3.3. Analysis by Type of Partner
9.3.3.1. Analysis by Year of Partnership and Type of Partner
9.3.3.2. Analysis by Type of Partnership and Type of Partner
9.3.3.3. Analysis by Type of Partner and Company Size
9.3.4. Analysis by Type of Therapy
9.3.4.1. Analysis by Type of Partnership and Type of Therapy
9.3.4.2. Analysis by Type of Partner and Type of Therapy
9.3.5. Analysis by Therapeutic Area
9.3.5.1. Analysis by Year of Partnership and Therapeutic Area
9.3.5.2. Analysis by Type of Partner and Therapeutic Area
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Analysis by Geography
9.3.8. Intercontinental and Intracontinental Agreements
10. GO-TO-MARKET STRATEGY
10.1. Chapter Overview
10.2. Marketing Strategies Adopted by Digital Therapeutic Developers
10.2.1. Participation in Global Events
10.2.2. Marketing on Social Media Platforms
10.2.3. Marketing on Online / Print Media Platforms
10.2.4. Undertaking Various Promotional Activities through Official Websites
10.2.5. Adoption of Different Business Models
10.2.5.1. B2C Business Model
10.2.5.2. B2B Business Model
10.2.5.2. B2B2C Business Model
10.2.6. Undertaking Various Promotional Activities through Product Add-ons
10.3. Concluding Remarks
11. BOWMAN CLOCK PRICING STRATEGY ANALYSIS
11.1. Chapter Overview
11.2. Bowman Strategy Clock
11.2.1. Two Dimensions of Bowman Strategy Clock
11.2.2. Eight Positions on Bowman Strategic Clock
11.3. Roots Analysis Framework
11.3.1. Methodology
11.3.2. Theoretical Framework and Price Evaluation Hypothesis
11.3.3. Results and Interpretation
11.3.3.1. Product Price Evaluation Matrix: Based on Status of Development
11.3.3.2. Product Price Evaluation Matrix: Based on Type of Solution
11.3.3.3. Product Price Evaluation Matrix: Based on Purpose of Solution
11.3.3.4. Product Price Evaluation Matrix: Based on Type of Therapy
11.3.3.5. Product Price Evaluation Matrix: Based on Therapeutic Area
11.3.3.6. Product Price Evaluation Matrix: Based on Prescription Requirement
11.3.3.7. Product Price Evaluation Matrix: Based on Duration of Course
11.3.3.8. Product Price Evaluation Matrix: Based on Distribution Channel
11.4. Concluding Remarks
12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Digital Therapeutics Market, 2022-2035
12.4. Digital Therapeutics Market: Analysis by Type of Solution, 2022-2035
12.4.1. Digital Therapeutics Market for Standalone Software Applications, 2022-2035
12.4.2. Digital Therapeutics Market for Combination Offerings focused on Software Application, Device and Personal Coach, 2022-2035
12.4.3. Digital Therapeutics Market for Combination Offerings focused on Software Application and Personal Coach, 2022-2035
12.4.4. Digital Therapeutics Market for Combination Offerings focused on Software Application and AI Support, 2022-2035
12.4.5. Digital Therapeutics Market for Combination Offerings focused on Software Application and Device), 2022-2035
12.4.6. Digital Therapeutics Market for Combination Offerings focused on Software Application, Device and AI Support), 2022-2035
12.4.7. Digital Therapeutics Market for Other Types of Solutions, 2022-2035
12.5. Digital Therapeutics Market: Analysis by Purpose of Solution, 2022-2035
12.5.1. Digital Therapeutics Market for Medication Replacement Solutions, 2022-2035
12.5.2. Digital Therapeutics Market for Medication Augmentation Solutions, 2022-2035
12.6. Digital Therapeutics Market: Analysis by Type of Therapy, 2022-2035
12.6.1. Digital Therapeutics Market for Curative Therapy, 2022-2035
12.6.2. Digital Therapeutics Market for Preventive Therapy, 2022-2035
12.7. Digital Therapeutics Market: Analysis by Business Model, 2022-2035
12.7.1. Digital Therapeutics Market for B2C Model, 2022-2035
12.7.2. Digital Therapeutics Market for B2B Model, 2022-2035
12.8. Digital Therapeutics Market: Analysis by Therapeutic Area, 2022-2035
12.8.1. Digital Therapeutics Market for Cardiovascular Disorders, 2022-2035
12.8.2. Digital Therapeutics Market for Chronic Pain, 2022-2035
12.8.3. Digital Therapeutics Market for Mental Health Problems, 2022-2035
12.8.4. Digital Therapeutics Market for Metabolic Disorders, 2022-2035
12.8.5. Digital Therapeutics Market for Neurological Disorders, 2022-2035
12.8.6. Digital Therapeutics Market for Respiratory Disorders, 2022-2035
12.8.7. Digital Therapeutics Market for Sleep Disorders, 2022-2035
12.8.8. Digital Therapeutics Market for Substance Use Disorders, 2022-2035
12.8.9. Digital Therapeutics Market for Other Disorders, 2022-2035
12.9. Digital Therapeutics Market: Analysis by Geography, 2022-2035
12.9.1. Digital Therapeutics Market in North America, 2022-2035
12.9.2. Digital Therapeutics Market in Europe, 2022-2035
12.9.3. Digital Therapeutics Market in Asia, 2022-2035
12.9.4. Digital Therapeutics Market in MENA, 2022-2035
12.9.5. Digital Therapeutics Market in Latin America, 2022-2035
12.9.6. Digital Therapeutics Market in Rest of the World, 2022-2035
12.10. Concluding Remarks
13. WOMEN DIGITAL HEALTH: AN EMERGING NEW CONCEPT
13.1. Introduction: Women Digital Health
13.2. Chapter Overview
13.3. Women’s Digital Health: Product Pipeline
13.3.1. Analysis by Type of Solution
13.3.2. Analysis by Status of Development
13.3.3. Analysis by Product Ratings
13.3.4. Analysis by Application Area
13.3.5. Analysis of Products by Different Stages of Pregnancy
13.3.6. Analysis by Purpose of Solution
13.3.7. Analysis by Type of End-Users
13.3.8. Analysis by Type of Solution and Application Area
13.4. Women’s Digital Health: Developer's Landscape
13.4.1. Analysis by Year of Establishment
13.4.2. Analysis by Company Size
13.4.3. Analysis by Location of Headquarters (Region-wise)
13.4.4. Analysis by Company Size and Region
13.4.5. Analysis by Location of Headquarters (Country-Wise)
13.4.6. Leading Players: Analysis by Number of Solutions
13.4.7. Regional Landscape: Analysis by Type of Solution
14. SWOT ANALYSIS
14.1. Chapter Overview
14.2. Comparison of SWOT Factors
14.2.1. Strengths
14.2.2. Weaknesses
14.2.3. Opportunities
14.2.4. Threats
14.2.5. Conclusion
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Ampersand Health
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Radhika Kamalia, Chief of Staffs to CEO and Strategy Lead
15.3. Canary Health
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Adam Kaufman, Ex-Chief Executive Officer
15.4. Dnurse Technology
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Cindy Zhang, Marketing Director
15.5. Embr Labs
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Healther Ritchie, Chief Strategy Officer
15.6. Exosystems
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Hooman Lee, Founder and Chief Executive Officer
15.7. Floreo
15.7.1. Company Snapshot
15.7.2. Interview Transcript: Vijay Ravindran, Chief Executive Officer
15.8. GAIA
15.8.1. Company Snapshot
15.8.2. Interview Transcript: Stan Sugarman, Chief Commercial Officer
15.9. Healios
15.9.1. Company Snapshot
15.9.2. Interview Transcript: Guilhem Dupnot , Founder and Chief Executive Officer
15.10. JOGGO Health
15.10.1. Company Snapshot
15.10.2. Interview Transcript: Siva Nadarajah, Co-Founder and President
15.11. metaMe Health
15.11.1. Company Snapshot
15.11.2. Interview Transcript: Tim Rudolphi, Chief Executive Officer
15.12. SelfBack
15.12.1. Company Snapshot
15.12.2. Interview Transcript: Soren Kleberg, Chief Executive Officer
15.13. Somatix
15.13.1. Company Snapshot
15.13.2. Interview Transcript: Eran Ofir, Ex-Chief Executive Officer
15.14. Tilak Healthcare
15.14.1. Company Snapshot
15.14.2. Interview Transcript: Edouard Gasser, Chief Executive Officer
15.15. Turnaround Health
15.15.1. Company Snapshot
15.15.2. Interview Transcript: Torin Block, Chief Executive Officer
15.16. Vida Health
15.16.1. Company Snapshot
15.16.2. Interview Transcript: Stephanie Tilenius, Co-Founder and Chief Executive Officer
15.17. Voluntis
15.17.1. Company Snapshot
15.17.2. Interview Transcript: Amelie Janson, Ex-Communication Manager
15.18. Wellthy Therapeutics
15.18.1. Company Snapshot
15.18.2. Interview Transcript: Palakh R Sarogi, Ex-Vice President Marketing, Arani Sarkra Ex-Senior Manager Consumer Marketing, and Yolande D’Mello, Ex-Marketing and Public Relations
15.19. Undisclosed
15.19.1. Interview Transcript: Anonymous, Founder and Chief Executive Officer
16. CONCLUDING REMARKS
17. APPENDIX 1: TABULATED DATA
18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Digital Health: Major Causes for Chronic Diseases
Figure 3.2 Historical Timeline of Digital Health: Analysis of Google Trends
Figure 3.3 Internet of Things: General Framework
Figure 3.4 Internet of Things: Applications in the Healthcare Sector
Figure 3.5 Prescription Digital Therapeutics: Process Map
Figure 3.6 Characteristics of a Digital Therapeutic Program: An Illustration
Figure 4.1 Digital Therapeutics: Distribution by Status of Development
Figure 4.2 Digital Therapeutics: Distribution by Type of Solution
Figure 4.3 Digital Therapeutics: Distribution by Type of Therapy
Figure 4.4 Digital Therapeutics: Distribution by Purpose of Solution
Figure 4.5 Digital Therapeutics: Distribution by Type of Therapy and Purpose of Solution
Figure 4.6 Digital Therapeutics: Distribution by Target Indication
Figure 4.7 Digital Therapeutics: Distribution by Therapeutic Area
Figure 4.8 Digital Therapeutics: Distribution by Target Population
Figure 4.9 Digital Therapeutic Solutions: Distribution by Prescription Requirements
Figure 4.10 Digital Therapeutic Solutions: Distribution by Duration of Course
Figure 4.11 Digital Therapeutic Solutions: Distribution by Cost of Solutions (USD)
Figure 4.12 Digital Therapeutic Developers: Distribution by Year of Establishment
Figure 4.13 Digital Therapeutics Developers: Distribution by Company Size
Figure 4.14 Digital Therapeutics Developers: Distribution by Business Model
Figure 4.15 Digital Therapeutics Developers: Distribution by Location of Headquarters
Figure 4.16 Leading Digital Therapeutics Developers: Distribution by Number of Digital Therapeutic Solutions
Figure 4.17 Leading Digital Therapeutics Developers: Distribution by Portfolio Strength, Therapeutic Area and Company Size (4-D Bubble Representation)
Figure 4.18 Digital Therapeutics: Distribution by Therapeutic Area and Company Size (Tree Map Representation)
Figure 4.19 Digital Therapeutics: Distribution of Regional Activity (World Map Representation)
Figure 5.1 Cardiovascular Disorders: Shift in Trends (2018-2023)
Figure 5.2 Product Competitiveness Analysis: Cardiovascular Disorders
Figure 5.3 Mental Health Problems: Shift in Trends (2018-2023)
Figure 5.4 Product Competitiveness Analysis: Mental Health Problems
Figure 5.5 Metabolic Disorders: Shift in Trends (2018-2023)
Figure 5.6 Product Competitiveness Analysis: Metabolic Disorders
Figure 5.7 Neurological Disorders: Shift in Trends (2018-2023)
Figure 5.8 Product Competitiveness Analysis: Neurological Disorders
Figure 5.9 Substance Use Disorders: Shift in Trends (2018-2023)
Figure 5.10 Product Competitiveness Analysis: Substance Use Disorders
Figure 5.11 Other Therapeutic Areas: Shift in Trends (2018-2023)
Figure 5.12 Product Competitiveness Analysis: Other Therapeutic Areas
Figure 6.1 Akili Interactive: Core Technologies and Benefits of Digital Products
Figure 6.2 Big Health: Digital Therapeutics Products and Clinical Trial Outcomes
Figure 6.3 WellDoc: Key Benefits of Diabetes Management Program
Figure 6.4 Wellthy Therapeutics: Diabetes Program
Figure 7.1 Key Methods to Validate Digital Therapeutic Solutions
Figure 7.2 Clinical Trial Analysis: Scope and Methodology
Figure 7.3 Clinical Trial Analysis: Cumulative Year-wise Trend of Trials by Trial Registration Year, Pre-2017-2022
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 7.6 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.7 Clinical Trial Analysis: Distribution by Type of Study
Figure 7.8 Clinical Trial Analysis: Distribution by Study Design
Figure 7.9 Clinical Trial Analysis: Distribution by Study Age
Figure 7.10 Clinical Trial Analysis: Distribution by Gender of Patients
Figure 7.11 Clinical Trial Analysis: Distribution of Patient Enrolled by Trial Registration Year
Figure 7.12 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 7.13 Clinical Trial Analysis: Distribution by Focus Area
Figure 7.14 Clinical Trial Analysis: Distribution of Trials by Geography
Figure 7.15 Clinical Trial Analysis: Distribution by Trial Registration Year, Recruitment Status and Geography
Figure 7.16 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 7.17 Clinical End-Points Analysis
Figure 7.18 Clinical Trials Analysis: Key Clinical End-Points for Metabolic Disorders
Figure 7.19 Clinical Trial Analysis: Primary and Secondary Clinical End-Points for Metabolic Disorders
Figure 8.1 Funding and Investment Analysis: Distribution of Instances by Year of Establishment and Type of Funding
Figure 8.2 Funding and Investment Analysis: Cumulative Year-wise Distribution of Instances, Pre-2019 - 2022
Figure 8.3 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, Pre-2019 - 2022 (USD Million)
Figure 8.4 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 8.5 Funding and Investment Analysis: Distribution of Instances by Year and Type of Funding, 2016 - 2022
Figure 8.6 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding, 2016- 2022 (USD Million)
Figure 8.7 Funding and Investment Analysis: Summary of Amount Invested, 2016-2022
Figure 8.9 Funding and Investment Analysis: Distribution of Instances and Amount Invested by Type of Therapy (USD Million)
Figure 8.10 Funding and Investment Analysis: Distribution of Instances by Year and Type of Therapy, 2016 - 2022
Figure 8.11 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Therapy, Pre-2019 - 2022 (USD Million)
Figure 8.12 Funding and Investment Analysis: Distribution of Instances by Therapeutic Area
Figure 8.13 Funding and Investment Analysis: Distribution of Amount Invested by Therapeutic Area (USD Million)
Figure 8.14 Funding and Investment Analysis: Distribution of Instances by Geography
Figure 8.15 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million)
Figure 8.16 Most Active Players: Distribution by Number of Instances
Figure 8.17 Most Active Players: Distribution by Amount Raised (USD Million)
Figure 8.18 Most Active Investors: Distribution by Number of Instances
Figure 8.19 Funding and Investment Summary, Pre-2019-2022 (USD Million)
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2016 - 2022
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership, Pre-2016 - 2022
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.6 Partnerships and Collaborations: Year-Wise Trend by Type of Partner, Pre-2016 - 2022
Figure 9.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 9.8 Partnerships and Collaborations: Distribution by Type of Partner and Company Size
Figure 9.9 Partnerships and Collaborations: Distribution by Type of Therapy
Figure 9.10 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Therapy
Figure 9.11 Partnerships and Collaborations: Distribution by Type of Partner and Type of Therapy
Figure 9.12 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 9.13 Partnerships and Collaborations: Year-Wise Trend by Therapeutic Area
Figure 9.14 Partnerships and Collaborations: Distribution by Type of Partner and Therapeutic Area
Figure 9.15 Most Active Players: Distribution by Number of Partnerships
Figure 9.16 Partnerships and Collaborations: Regional Distribution
Figure 9.17 Partnerships and Collaborations: Country-Wise Distribution
Figure 9.18 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.1 Go-to-Market Strategy: Commonly Used Social Media Platforms
Figure 10.2 Go-to-Market Strategy: Online / Print Media Platforms
Figure 10.3 Go-to-Market Strategy: Promotional Activities through Official Websites
Figure 10.4 Go-to-Market Strategy: Adoption of Different Business Model
Figure 10.5 Go-to-Market Strategy: Promotional Activities through Product Websites
Figure 10.6 Go-to-Market Strategy: Key Marketing Strategies for New Entrants
Figure 10.7 Go-to-Market Strategy: Industry Stakeholder Opinions
Figure 11.1 Digital Therapeutics: Bowman Clock Pricing Strategy Matrix
Figure 11.2 Digital Therapeutics: Bowman Clock Pricing Strategy Graphical Interpretation
Figure 12.1 Overall Digital Therapeutics Market, 2022-2035 (USD Million)
Figure 12.2 Digital Therapeutics Market: Distribution by Type of Solution, 2022-2035 (USD Million)
Figure 12.3 Digital Therapeutics Market for Standalone Software Applications 2022-2035 (USD Million)
Figure 12.4 Digital Therapeutics Market for Combination Offerings of Software Application, Device and Personal Coach, 2022-2035 (USD Million)
Figure 12.5 Digital Therapeutics Market for Combination Offerings of Software Application and Personal Coach, 2022-2035 (USD Million)
Figure 12.6 Digital Therapeutics Market for Combination Offerings of Software Application and AI Support, 2022-2035 (USD Million)
Figure 12.7 Digital Therapeutics Market for Combination Offerings of Software Application and Device, 2022-2035 (USD Million)
Figure 12.8 Digital Therapeutics Market for Combination Offerings of Software Application, Device and AI Support, 2022-2035 (USD Million)
Figure 12.9 Digital Therapeutics Market for Other Types of Solutions, 2022-2035 (USD Million)
Figure 12.10 Digital Therapeutics Market: Distribution by Purpose of Solution, 2022-2035
Figure 12.11 Digital Therapeutics Market for Medication Replacement Solutions, 2022-2035 (USD Million)
Figure 12.12 Digital Therapeutics Market for Medication Augmentation Solutions, 2022-2035 (USD Million)
Figure 12.13 Digital Therapeutics Market: Distribution by Type of Therapy, 2022-2035 (USD Million)
Figure 12.14 Digital Therapeutics Market for Curative Therapies, 2022-2035 (USD Million)
Figure 12.15 Digital Therapeutics Market for Preventive Therapies, 2022-2035 (USD Million)
Figure 12.16 Digital Therapeutics Market: Distribution by Business Model, 2022-2035 (USD Million)
Figure 12.17 Digital Therapeutics Market for B2C Model, 2022-2035 (USD Million)
Figure 12.18 Digital Therapeutics Market for B2B Model, 2022-2035 (USD Million)
Figure 12.19 Digital Therapeutics Market: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 12.20 Digital Therapeutics Market for Cardiovascular Disorders, 2022-2035 (USD Million)
Figure 12.21 Digital Therapeutics Market for Chronic Pain, 2022-2035 (USD Million)
Figure 12.22 Digital Therapeutics Market for Mental Health Problems, 2022-2035 (USD Million)
Figure 12.23 Digital Therapeutics Market for Metabolic Disorders, 2022-2035 (USD Million)
Figure 12.24 Digital Therapeutics Market for Neurological Disorders, 2022-2035 (USD Million)
Figure 12.25 Digital Therapeutics Market for Respiratory Disorders, 2022-2035 (USD Million)
Figure 12.26 Digital Therapeutics Market for Sleep Disorders 2022-2035 (USD Million)
Figure 12.27 Digital Therapeutics Market for Substance Use Disorders, 2022-2035 (USD Million)
Figure 12.28 Digital Therapeutics Market for Other Disorders, 2022-2035 (USD Million)
Figure 12.29 Digital Therapeutics Market: Distribution by Geography, 2022-2035 (USD Million)
Figure 12.30 Digital Therapeutics Market in North America, 2022-2035 (USD Million)
Figure 12.31 Digital Therapeutics Market in Europe, 2022-2035 (USD Million)
Figure 12.32 Digital Therapeutics Market in Asia, 2022-2035 (USD Million)
Figure 12.33 Digital Therapeutics Market in MENA, 2022-2035 (USD Million
Figure 12.34 Digital Therapeutics Market in Latin America, 2022-2035 (USD Million
Figure 12.35 Digital Therapeutics Market in Rest of the World, 2022-2035 (USD Million)
Figure 13.1 Women’s Digital Health: Distribution by Type of Solution
Figure 13.2 Women’s Digital Health: Distribution by Status of Development
Figure 13.3 Women’s Digital Health: Distribution by Product Ratings
Figure 13.4 Women’s Digital Health: Distribution by Application Area
Figure 13.5 Women’s Digital Health: Distribution of Products used during Stages of Pregnancy
Figure 13.6 Women’s Digital Health: Distribution by Purpose of Solution
Figure 13.7 Women’s Digital Health: Distribution by Type of End-Users
Figure 13.8 Women’s Digital Health: Distribution by Type of Solution and Application Area
Figure 13.9 Women’s Digital Health Developers: Distribution by Year of Establishment
Figure 13.10 Women’s Digital Health Developers: Distribution by Company Size
Figure 13.11 Women’s Digital Health Developers: Distribution by Location of Headquarters (Region-wise)
Figure 13.12 Women’s Digital Health Developers: Distribution by Company Size and Region
Figure 13.13 Women’s Digital Health Developers: Distribution by Location of Headquarters (Country-wise)
Figure 13.14 Leading Players: Distribution by Number of Solutions
Figure 13.15 Regional Landscape: Distribution by Type of Solution
Figure 14.1 Digital Therapeutics: Overview of SWOT Analysis
Figure 14.2 Comparison of SWOT Factors: Harvey Ball Analysis
Table 4.1 Digital Therapeutics: Information on Status of Development and Launch Year
Table 4.2 Digital Therapeutics: Information on Type of Solution
Table 4.3 Digital Therapeutics: Information on Type of Therapy and Purpose of Solution
Table 4.4 Digital Therapeutics: Information on Target Indication(s), Therapeutic Area and Target Population
Table 4.5 Digital Therapeutic Solutions: Information on Prescription Requirement, Duration of Course and Cost of Solution
Table 4.6 Digital Therapeutics: List of Developers
Table 6.1 Digital Therapeutics: List of Companies Profiled
Table 6.2 Akili Interactive: Company Snapshot
Table 6.3 Akili Interactive: Digital Therapeutic Solutions Portfolio
Table 6.4 Akili Interactive: Recent Developments and Future Outlook
Table 6.5 Big Health: Company Snapshot
Table 6.6 Big Health: Digital Therapeutic Solutions Portfolio
Table 6.7 Big Health: Recent Developments and Future Outlook
Table 6.8 dreem: Company Snapshot
Table 6.9 dreem: Digital Therapeutic Solutions Portfolio
Table 6.10 dreem: Recent Developments and Future Outlook
Table 6.11 Kaia Health: Company Snapshot
Table 6.12 Kaia Health: Digital Therapeutic Solutions Portfolio
Table 6.13 Kaia Health: Recent Developments and Future Outlook
Table 6.14 MindMaze: Company Snapshot
Table 6.15 MindMaze: Digital Therapeutic Solutions Portfolio
Table 6.16 MindMaze: Recent Developments and Future Outlook
Table 6.17 Omada Health: Company Snapshot
Table 6.18 Omada Health: Digital Therapeutic Solutions Portfolio
Table 6.19 Omada Health: Recent Developments and Future Outlook
Table 6.20 Pear Therapeutics: Company Snapshot
Table 6.21 Pear Therapeutics: Digital Therapeutic Solutions Portfolio
Table 6.22 Pear Therapeutics: Recent Developments and Future Outlook
Table 6.23 Vida Health: Company Snapshot
Table 6.24 Vida Health: Digital Therapeutic Solutions Portfolio
Table 6.25 Vida Health: Recent Developments and Future Outlook
Table 6.26 Voluntis: Company Snapshot
Table 6.27 Voluntis: Digital Therapeutic Solutions Portfolio
Table 6.28 Voluntis: Recent Developments and Future Outlook
Table 6.29 WellDoc: Company Snapshot
Table 6.30 WellDoc: Digital Therapeutic Solutions Portfolio
Table 6.31 WellDoc: Recent Developments and Future Outlook
Table 6.32 Wellthy Therapeutics: Company Snapshot
Table 6.33 Wellthy Therapeutics: Digital Therapeutic Solutions Portfolio
Table 6.34 Wellthy Therapeutics: Recent Developments and Future Outlook
Table 8.1 Digital Therapeutics: Funding and Investments, Information on Year of Investment, Type of Funding, Amount Invested and Investor(s), 2016 - 2022
Table 8.2 Digital Therapeutics: Funding and Investments, Information on Year of Establishment, Location of Headquarters of Recipients, Type of Therapy and Therapeutic Area
Table 9.1 Digital Therapeutics: List of Collaborations
Table 9.2 Digital Therapeutics: Partnerships and Collaborations, Information on Type of Agreement (Region-wise and Geography-wise)
Table 10.1 Digital Therapeutics: Summary of Marketing Strategies
Table 10.2 Go-to-Market Strategy: Product Specific Websites
Table 11.1 Product Price Evaluation Matrix: Based on Status of Development
Table 11.2 Product Price Evaluation Matrix: Based on Type of Solution
Table 11.3 Product Price Evaluation Matrix: Based on Purpose of Solution
Table 11.4 Product Price Evaluation Matrix: Based on Type of Therapy
Table 11.5 Product Price Evaluation Matrix: Based on Therapeutic Area
Table 11.6 Product Price Evaluation Matrix: Based on Prescription Requirement
Table 11.7 Product Price Evaluation Matrix: Based on Duration of Course
Table 11.8 Product Price Evaluation Matrix: Based on Distribution Channel
Table 15.1 Company Snapshot: Ampersand Health
Table 15.2 Company Snapshot: Canary Health
Table 15.3 Company Snapshot: Dnurse Technology
Table 15.4 Company Snapshot: Embr Labs
Table 15.5 Company Snapshot: Exosystems
Table 15.6 Company Snapshot: Floreo
Table 15.7 Company Snapshot: GAIA
Table 15.8 Company Snapshot: Healios
Table 15.9 Company Snapshot: JOGGO Health
Table 15.10 Company Snapshot: metaMe Health
Table 15.11 Company Snapshot: SelfBack
Table 15.12 Company Snapshot: Somatix
Table 15.13 Company Snapshot: Tilak Healthcare
Table 15.14 Company Snapshot: Turnaround Health
Table 15.15 Company Snapshot: Vida Health
Table 15.16 Company Snapshot: Voluntis
Table 15.17 Company Snapshot: Wellthy Therapeutics
Table 17.1 Digital Therapeutics: Distribution by Status of Development
Table 17.2 Digital Therapeutics: Distribution by Type of Solution
Table 17.3 Digital Therapeutics: Distribution by Type of Therapy
Table 17.4 Digital Therapeutics: Distribution by Purpose of Solution
Table 17.5 Digital Therapeutics: Distribution by Type of Therapy and Purpose of Solution
Table 17.6 Digital Therapeutics: Distribution by Target Indication(s)
Table 17.7 Digital Therapeutics: Distribution by Therapeutic Area
Table 17.8 Digital Therapeutics: Distribution by Target Population
Table 17.9 Digital Therapeutics: Distribution by Prescription Requirement
Table 17.10 Digital Therapeutics: Distribution by Duration of Course
Table 17.11 Digital Therapeutics: Distribution by Cost of Solution (USD)
Table 17.12 Digital Therapeutics Developers: Distribution by Year of Establishment
Table 17.13 Digital Therapeutics Developers: Distribution by Company Size
Table 17.14 Digital Therapeutics Developers: Distribution by Business Model
Table 17.15 Digital Therapeutics Developers: Distribution by Location of Headquarters
Table 17.16 Leading Digital Therapeutics Developers: Distribution by Number of Digital Therapeutics Solutions
Table 17.17 Leading Digital Therapeutics Developers: Distribution by Portfolio Strength, Therapeutic Area and Company Size (4-D Bubble Representation)
Table 17.18 Digital Therapeutics: Distribution by Therapeutic Area and Company Size (Tree Map Representation)
Table 17.19 Digital Therapeutics: Distribution by Regional Activity
Table 17.20 Cardiovascular Disorders: Shift in Trends (2018 - 2023)
Table 17.21 Mental Health Problems: Shift in Trends (2018 - 2023)
Table 17.22 Metabolic Disorders: Shift in Trends (2018 - 2023)
Table 17.23 Neurological Disorders: Shift in Trends (2018 - 2023)
Table 17.24 Substance Use Disorders: Shift in Trends (2018 - 2023)
Table 17.25 Other Therapeutic Areas: Shift in Trends (2018 - 2023)
Table 17.26 Clinical Trial Analysis: Scope and Methodology
Table 17.27 Clinical Trial Analysis: Cumulative Year-wise Trend of Trials by Trial Registration Year, Pre-2017-2022
Table 17.28 Clinical Trial Analysis: Distribution by Trial Status
Table 17.29 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 17.30 Clinical Trial Analysis: Distribution by Trial Phase
Table 17.31 Clinical Trial Analysis: Distribution by Type of Study
Table 17.32 Clinical Trial Analysis: Distribution by Study Design
Table 17.33 Clinical Trial Analysis: Distribution by Study Age
Table 17.34 Clinical Trial Analysis: Distribution by Gender of Patients
Table 17.35 Clinical Trial Analysis: Distribution of Patient Enrolled by Trial Registration Year
Table 17.36 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 17.37 Clinical Trial Analysis: Distribution by Focus Area
Table 17.38 Clinical Trial Analysis: Distribution of Trials by Geography
Table 17.39 Clinical Trial Analysis: Distribution by Trial Registration Year, Recruitment Status and Geography
Table 17.40 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 17.41 Clinical End-Points Analysis
Table 17.42 Clinical Trials Analysis: Key Clinical End-Points for Metabolic Disorders
Table 17.43 Clinical Trial Analysis: Primary and Secondary Clinical End-Points for Metabolic Disorders
Table 17.44 Funding and Investment Analysis: Distribution of Instances by Year of Establishment and Type of Funding
Table 17.45 Funding and Investment Analysis: Cumulative Year-wise Distribution of Instances, Pre-2019 - 2022
Table 17.46 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, Pre-2019 - 2022 (USD Million)
Table 17.47 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 17.48 Funding and Investment Analysis: Distribution of Instances by Year and Type of Funding, 2016 - 2022
Table 17.49 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding, 2016- 2022 (USD Million)
Table 17.50 Funding and Investment Analysis: Summary of Amount Invested, 2016-2022
Table 17.51 Funding and Investment Analysis: Distribution of Instances and Amount Invested by Type of Therapy (USD Million)
Table 17.52 Funding and Investment Analysis: Distribution of Instances by Year and Type of Therapy, 2016 - 2022
Table 17.53 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Therapy, Pre-2019 - 2022 (USD Million)
Table 17.54 Funding and Investment Analysis: Distribution of Instances by Therapeutic Area
Table 17.55 Funding and Investment Analysis: Distribution of Amount Invested by Therapeutic Area (USD Million)
Table 17.56 Funding and Investment Analysis: Distribution of Instances by Geography
Table 17.57 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million)
Table 17.58 Most Active Players: Distribution by Number of Instances
Table 17.59 Most Active Players: Distribution by Amount Raised (USD Million)
Table 17.60 Most Active Investors: Distribution by Number of Instances
Table 17.61 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2016-2022
Table 17.62 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.63 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership, Pre-2016-2022
Table 17.64 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Table 17.65 Partnerships and Collaborations: Distribution by Type of Partner
Table 17.66 Partnerships and Collaborations: Year-Wise Trend by Type of Partner, Pre-2016-2022
Table 17.67 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 17.68 Partnerships and Collaborations: Distribution by Type of Partner and Company Size
Table 17.69 Partnerships and Collaborations: Distribution by Type of Therapy
Table 17.70 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Therapy
Table 17.71 Partnerships and Collaborations: Distribution by Type of Partner and Type of Therapy
Table 17.72 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 17.73 Partnerships and Collaborations: Year-Wise Trend by Therapeutic Area
Table 17.74 Partnerships and Collaborations: Distribution by Type of Partner and Therapeutic Area
Table 17.75 Most Active Players: Distribution by Number of Partnerships
Table 17.76 Partnerships and Collaborations: Regional Distribution
Table 17.77 Partnerships and Collaborations: Country-Wise Distribution
Table 17.78 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 17.79 Go-to-Market Strategy: Commonly Used Social Media Platforms
Table 17.80 Go-to-Market Strategy: Online / Print Media Platforms
Table 17.81 Go-to-Market Strategy: Promotional Activities through Official Websites
Table 17.82 Go-to-Market Strategy: Adoption of Different Business Model
Table 17.83 Go-to-Market Strategy: Promotional Activities through Product Websites
Table 17.84 Overall Digital Therapeutics Market, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.85 Digital Therapeutics Market: Distribution by Type of Solution, 2022-2035 (USD Million)
Table 17.86 Digital Therapeutics Market for Standalone Software Applications, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.87 Digital Therapeutics Market for Combination Offerings of Software Application, Device and Personal Coach, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.88 Digital Therapeutics Market for Combination Offerings of Software Application and Personal Coach, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.89 Digital Therapeutics Market for Combination Offerings of Software Application and AI Support, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.90 Digital Therapeutics Market for Combination Offerings of Software Application and Device, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.91 Digital Therapeutics Market for Combination Offerings of Software Application, Device and AI Support, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.92 Digital Therapeutics Market for Other Type of Solutions, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.93 Digital Therapeutics Market: Distribution by Purpose of Solution, 2022-2035 (USD Million)
Table 17.94 Digital Therapeutics Market for Medication Replacement Solutions, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.95 Digital Therapeutics Market for Medication Augmentation Solutions, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.96 Global Digital Therapeutics Market: Distribution by Type of Therapy, 2022 and 2035 (USD Million)
Table 17.97 Digital Therapeutics Market for Curative Therapy, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.98 Digital Therapeutics Market for Preventive Therapy, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.99 Global Digital Therapeutics Market: Distribution by Business Model, 2022-2035 (USD Million)
Table 17.100 Digital Therapeutics Market for B2C Model, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.101 Digital Therapeutics Market for B2B Model, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.102 Global Digital Therapeutics Market: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 17.103 Digital Therapeutics Market for Cardiovascular Disorders, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.104 Digital Therapeutics Market for Chronic Pain, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.105 Digital Therapeutics Market for Mental Health Problems, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.106 Digital Therapeutics Market for Metabolic Disorders, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.107 Digital Therapeutics Market for Neurological Disorders, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.108 Digital Therapeutics Market for Respiratory Disorders, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.109 Digital Therapeutics Market for Sleep Disorders, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.110 Digital Therapeutics Market for Substance Use Disorders, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.111 Digital Therapeutics Market for Other Disorders, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.112 Global Digital Therapeutics Market: Distribution by Geography, 2022 and 2035
Table 17.113 Digital Therapeutics Market in North America, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.114 Digital Therapeutics Market in Europe, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.115 Digital Therapeutics Market in Asia, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.116 Digital Therapeutics Market in MENA, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.117 Digital Therapeutics Market in Latin America, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.118 Digital Therapeutics Market in Rest of the World, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.119 Women’s Digital Health: Distribution by Type of Solution
Table 17.120 Women’s Digital Health: Distribution by Status of Development
Table 17.121 Women’s Digital Health: Distribution by Product Ratings
Table 17.122 Women’s Digital Health: Distribution by Application Area
Table 17.123 Women’s Digital Health: Distribution by Products Usage with respect to Pregnancy
Table 17.124 Women’s Digital Health: Distribution by Purpose of Solution
Table 17.125 Women’s Digital Health: Distribution by Type of End-Users
Table 17.126 Women’s Digital Health: Distribution by Type of Solution and Application Area
Table 17.127 Women’s Digital Health Developers: Distribution by Year of Establishment
Table 17.128 Women’s Digital Health Developers: Distribution by Company Size
Table 17.129 Women’s Digital Health Developers: Distribution by Location of Headquarters (Region-wise)
Table 17.130 Women’s Digital Health Developers: Distribution by Company Size and Region
Table 17.131 Women’s Digital Health Developers: Distribution by Location of Headquarters (Country-wise)
Table 17.132 Leading Players: Distribution by Number of Solutions
Table 17.133 Regional Landscape: Distribution by Type of Solution
The following companies and organizations have been mentioned in the report:
Source 1: https://dtxalliance.org/understanding-dtx
Source 2: https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES